<DOC>
	<DOCNO>NCT02342041</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability pharmacokinetics SUVN-G3031 healthy male subject follow single multiple ascending dos .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics SUVN-G3031 Healthy Subjects</brief_title>
	<detailed_description>This single multiple ascend dose study assess safety , tolerability pharmacokinetics SUVN-G3031 administer orally day healthy male subject . The study conduct double-blind condition . The primary objective evaluate safety tolerability SUVN-G3031 follow oral administration single multiple ascend dos estimate maximum tolerated dose SUVN-G3031 , possible . The secondary objective evaluate single repeat dose plasma pharmacokinetics follow oral administration single multiple ascend dos SUVN-G3031 healthy male subject .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>â€¢ Healthy male age 18 45 year BMI 18 30 kg/m2 , ( inclusive ) . Standard exclusion criterion Phase 1 clinical trial healthy subject . History clinically significant disease disorder , opinion Investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate History presence GI , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug judge Investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>SUVN-G3031</keyword>
	<keyword>histamine 3 ( H3 ) receptor inverse agonist</keyword>
	<keyword>first human</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tolerability</keyword>
	<keyword>single dose</keyword>
	<keyword>repeat dose</keyword>
</DOC>